Parabilis Medicines

The departing director of the US Food and Drug Administration’s Center for Drug Evaluation and Research believes her staff is in “the best place possible” as it enters the new year and a new administr

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection

Recent biopharmaceutical venture capital financings reflect a worldly investment view, even at the $100m-plus mega-round level where the largest investments tend to be more frequent in the US. The six

FogPharma ended 2022 with a big cash haul – $178m from a series D venture capital round – and in 2023 achieved a couple of big milestones that helped the company raise its next big financing this yea